EUVIMEDEUVIMED entdecken
Crossref

Development and characterisation of a novel inhibitory anti-GH monoclonal antibody

Man Lu, Chantal Buckley, Yue Wang iD, Ries J Langley, Jo K Perry iD

Journal of Molecular Endocrinology · 2023

DOI: 10.1530/jme-23-0071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Endocrinology, 2023. Verfasst von Man Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liggins Institute, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Growth Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excess growth hormone (GH) has been implicated in multiple cancer types and there is increasing interest in the development of therapeutic inhibitors targeting GH–GH receptor (GHR) signalling. Here we describe a panel of anti-GH monoclonal antibodies (mAbs) generated using a hybridoma approach and identify two novel inhibitory mAbs (1-8-2 and 1-46-3) that neutralised GH signalling. mAbs 1-8-2 and 1-46-3 exhibited strong inhibitory activity against GH-dependent cell growth in a Ba/F3-GHR cell viability assay, with EC 50 values of 1.00 ± 0.27 and 0.5 ± 0.1 µg/mL, respectively. Cross-reactivity with the human placental hormones, placental lactogen (PL) and placental GH, was observed by ELISA, but neither antibody cross-reacted with mouse GH or human prolactin (PRL). mAb 1-8-2 had a binding affinity for GH of K D 0.62 ± 0.5 nM, while mAb 1-46-3 had a K D of 2.68 ± 0.53 nM, as determined by bio-layer interferometry. mAb 1-46-3 inhibited GH-dependent signal transduction in T-47D and LNCaP cancer cell lines and reduced GH-dependent cell growth and migration in the breast cancer cell line T-47D. mAb 1-46-3 inhibited T-47D cell viability more effectively than the GHR antagonist B2036. In conclusion, we describe two novel inhibitory anti-GH mAbs and provide in vitro evidence supporting development of these entities as anti-cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalGrowth HormoneAnimalsFemaleHumansMicePregnancyCell LinePlacentaReceptors, SomatotropinSignal TransductionHuman Growth Hormone

Stichwörter der Autor:innen

antagonistantibodycancergrowth hormone

Substanzen

Antibodies, MonoclonalGrowth HormoneReceptors, SomatotropinpegvisomantHuman Growth Hormone

Autor:innen und Institutionen

  • Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.
  • Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.

ORCID-Profile: Yue Wang, Jo K Perry

Zitieren

APA

Lu, M., Buckley, C., Wang, Y., Langley, R. J., & Perry, J. K. (2023). Development and characterisation of a novel inhibitory anti-GH monoclonal antibody. Journal of Molecular Endocrinology. https://doi.org/10.1530/jme-23-0071

Vancouver

Lu M, Buckley C, Wang Y, Langley RJ, Perry JK. Development and characterisation of a novel inhibitory anti-GH monoclonal antibody. Journal of Molecular Endocrinology. 2023. doi:10.1530/jme-23-0071

BibTeX
@article{Lu2023,
  author = {Lu, Man and Buckley, Chantal and Wang, Yue and Langley, Ries J and Perry, Jo K},
  title = {Development and characterisation of a novel inhibitory anti-GH monoclonal antibody},
  journal = {Journal of Molecular Endocrinology},
  year = {2023},
  doi = {10.1530/jme-23-0071}
}
Kostenlos starten →